This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (209)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in JAMA  Topic Collections  • Cardiovascular System  • Review  • Randomized Controlled Trial  • Drug Therapy  • Adverse Effects  • Congestive Heart Failure/ Cardiomyopathy  • Alert me on articles by topic  Social Bookmarking   What's this?

A Pooled Analysis of Randomized Controlled Trials

Jonathan D. Sackner-Bernstein, MD; Marcin Kowalski, MD; Marshal Fox, MD; Keith Aaronson, MD, MS

JAMA. 2005;293:1900-1905.

Context  Nesiritide improves symptoms in patients with acutely decompensated heart failure compared with placebo and appears to be safer than dobutamine. Its short-term safety relative to standard diuretic and vasodilator therapies is less clear.

Objective  To investigate the safety of nesiritide relative to noninotrope-based control therapies, primarily consisting of diuretics or vasodilators.

Data Sources  Primary reports of completed clinical trials as of December 2004 were obtained from the US Food and Drug Administration (FDA), the study sponsor (Scios Inc), a PubMed literature search using the terms nesiritide, clinical trials, and humans, and a manual search of annual meetings of 3 heart associations.

Study Selection  Of 12 randomized controlled trials evaluating nesiritide, 3 met all inclusion criteria: randomized double-blind study of patients with acutely decompensated heart failure, therapy administered as single infusion (6 hours), inotrope not mandated as control, and reported 30-day mortality.

Data Extraction  Data were extracted from FDA and sponsor documents and corroborated with published articles when available. Thirty-day survival was assessed by meta-analysis using a fixed-effects model and time-dependent risk by Kaplan-Meier analysis with Cox proportional hazards regression modeling. Where deaths were described within a range of days after treatment, an extreme assumption was made favoring nesiritide over control therapy, an approach relevant to the time-dependent analyses.

Data Synthesis  In the 3 trials, 485 patients were randomized to nesiritide and 377 to control therapy. Death within 30 days tended to occur more often among patients randomized to nesiritide therapy (35 [7.2%] of 485 vs 15 [4.0%] of 377 patients; risk ratio from meta-analysis, 1.74; 95% confidence interval [CI], 0.97-3.12; P = .059; and hazard ratio after adjusting for study, 1.80; 95% CI, 0.98-3.31; P = .057).

Conclusions  Compared with noninotrope-based control therapy, nesiritide may be associated with an increased risk of death after treatment for acutely decompensated heart failure. The possibility of an increased risk of death should be investigated in a large-scale, adequately powered, controlled trial before routine use of nesiritide for acutely decompensated heart failure.

Author Affiliations: Clinical Scholars Program, Division of Cardiology, North Shore University Hospital, Manhasset, NY (Dr Sackner-Bernstein); Department of Medicine, St Luke’s-Roosevelt Hospital Center, New York, NY (Drs Kowalski and Fox); and Division of Cardiovascular Medicine, University of Michigan, Ann Arbor (Dr Aaronson).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Risk of Death With Nesiritide
Andrew J. Burger
JAMA. 2005;294(8):897.
EXTRACT | FULL TEXT  

Risk of Death With Nesiritide
Justine Schuller Gortney and Kalen B. Porter
JAMA. 2005;294(8):897-898.
EXTRACT | FULL TEXT  

Risk of Death With Nesiritide—Reply
Jonathan D. Sackner-Bernstein and Keith Aaronson
JAMA. 2005;294(8):898.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Reconsidering the Role for Digoxin in the Management of Acute Heart Failure Syndromes
Gheorghiade and Braunwald
JAMA 2009;302:2146-2147.
FULL TEXT  

Intravenous therapy for hypertensive emergencies, part 1
Rhoney and Peacock
Am J Health Syst Pharm 2009;66:1343-1352.
ABSTRACT | FULL TEXT  

Perioperative manipulation of the circulation in children with congenital heart disease
Shekerdemian
Heart 2009;95:1286-1296.
FULL TEXT  

Are BNP Changes During Hospitalization for Heart Failure a Reliable Surrogate for Predicting the Effects of Therapies on Post-Discharge Mortality?
Gheorghiade and Pang
J Am Coll Cardiol 2009;53:2349-2352.
FULL TEXT  

End points for clinical trials in acute heart failure syndromes.
Allen et al.
J Am Coll Cardiol 2009;53:2248-2258.
ABSTRACT | FULL TEXT  

Cinaciguat (BAY 58-2667) Improves Cardiopulmonary Hemodynamics in Patients With Acute Decompensated Heart Failure
Lapp et al.
Circulation 2009;119:2781-2788.
ABSTRACT | FULL TEXT  

2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation
Hunt et al.
J Am Coll Cardiol 2009;53:e1-e90.
FULL TEXT  

2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation
Jessup et al.
J Am Coll Cardiol 2009;53:1343-1382.
FULL TEXT  

2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation
2009 WRITING GROUP TO REVIEW NEW EVIDENCE AND UPDA et al.
Circulation 2009;119:1977-2016.
FULL TEXT  

2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation
2005 WRITING COMMITTEE MEMBERS et al.
Circulation 2009;119:e391-e479.
FULL TEXT  

Acute heart failure syndromes.
Gheorghiade and Pang
J Am Coll Cardiol 2009;53:557-573.
ABSTRACT | FULL TEXT  

Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment.
Flaherty et al.
J Am Coll Cardiol 2009;53:254-263.
ABSTRACT | FULL TEXT  

Heart Failure and Cardiac Pulmonary Edema
Hollenberg
ACCP Crit Care Med Brd Rev 2009;20:117-128.
FULL TEXT  

Novel Bifunctional Natriuretic Peptides as Potential Therapeutics
Dickey et al.
J. Biol. Chem. 2008;283:35003-35009.
ABSTRACT | FULL TEXT  

Elevated Afterload, Neuroendocrine Stimulation, and Human Heart Failure Increase BNP Levels and Inhibit Preload-Dependent SERCA Upregulation
Toischer et al.
Circ Heart Fail 2008;1:265-271.
ABSTRACT | FULL TEXT  

Effects of Continuous Aortic Flow Augmentation in Patients With Exacerbation of Heart Failure Inadequately Responsive to Medical Therapy: Results of the Multicenter Trial of the Orqis Medical Cancion System for the Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy (MOMENTUM)
Greenberg et al.
Circulation 2008;118:1241-1249.
ABSTRACT | FULL TEXT  

Sodium nitroprusside for advanced low-output heart failure.
Mullens et al.
J Am Coll Cardiol 2008;52:200-207.
ABSTRACT | FULL TEXT  

Vasodilator therapy for decompensated heart failure.
Yancy
J Am Coll Cardiol 2008;52:208-210.
FULL TEXT  

The Tumultuous Journey of Nesiritide: Past, Present, and Future
Burnett and Korinek
Circ Heart Fail 2008;1:6-8.
FULL TEXT  

Safety and Efficacy of Outpatient Nesiritide in Patients With Advanced Heart Failure: Results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) Trial
Yancy et al.
Circ Heart Fail 2008;1:9-16.
ABSTRACT | FULL TEXT  

A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach
Pang et al.
Eur Heart J 2008;29:816-824.
ABSTRACT | FULL TEXT  

Impact of Treatment Guidelines on Clinical and Economic Outcomes of Acute Decompensated Heart Failure
DiDomenico et al.
The Annals of Pharmacotherapy 2008;42:327-333.
ABSTRACT | FULL TEXT  

Contemporary Trends in the Pharmacological and Extracorporeal Management of Heart Failure: A Nephrologic Perspective
Kazory and Ross
Circulation 2008;117:975-983.
ABSTRACT | FULL TEXT  

Overview of emerging pharmacologic agents for acute heart failure syndromes
De Luca et al.
Eur J Heart Fail 2008;10:201-213.
ABSTRACT | FULL TEXT  

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy
Turner et al.
NEJM 2008;358:252-260.
ABSTRACT | FULL TEXT  

Predictors of mortality in adult patients with congestive heart failure receiving nesiritide Retrospective analysis showing a potential adverse interaction between neseritide and acute renal dysfunction
Iglesias et al.
Nephrol Dial Transplant 2008;23:144-153.
ABSTRACT | FULL TEXT  

Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients With Acute Heart Failure: The VERITAS Randomized Controlled Trials
McMurray et al.
JAMA 2007;298:2009-2019.
ABSTRACT | FULL TEXT  

Using Homeostatic Peptides in Decompensated Heart Failure: A Reasonable Paradigm But a Flawed Practice?
Silver and Yancy
J Am Coll Cardiol 2007;50:1841-1843.
FULL TEXT  

Effect of nesiritide on renal function in patients admitted for decompensated heart failure
Arora et al.
QJM 2007;100:699-706.
ABSTRACT | FULL TEXT  

Suppression of Central Sleep Apnea by Continuous Positive Airway Pressure and Transplant-Free Survival in Heart Failure: A Post Hoc Analysis of the Canadian Continuous Positive Airway Pressure for Patients With Central Sleep Apnea and Heart Failure Trial (CANPAP)
Arzt et al.
Circulation 2007;115:3173-3180.
ABSTRACT | FULL TEXT  

Clinical trials update from the American College of Cardiology 2007: ALPHA, EVEREST, FUSION II, VALIDD, PARR-2, REMODEL, SPICE, COURAGE, COACH, REMADHE, pro-BNP for the evaluation of dyspnoea and THIS-diet
Cleland et al.
Eur J Heart Fail 2007;9:740-745.
ABSTRACT | FULL TEXT  

Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure: The SURVIVE Randomized Trial
Mebazaa et al.
JAMA 2007;297:1883-1891.
ABSTRACT | FULL TEXT  

Hospital Policies for Treatment of Acute Decompensated Heart Failure
Vats et al.
The Annals of Pharmacotherapy 2007;41:562-567.
ABSTRACT | FULL TEXT  

Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure: The EVEREST Outcome Trial
Konstam et al.
JAMA 2007;297:1319-1331.
ABSTRACT | FULL TEXT  

Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart Failure: The EVEREST Clinical Status Trials
Gheorghiade et al.
JAMA 2007;297:1332-1343.
ABSTRACT | FULL TEXT  

Climbing the Mountain of Acute Decompensated Heart Failure: The EVEREST Trials
Yancy
JAMA 2007;297:1374-1376.
FULL TEXT  

Management of acute decompensated heart failure
Allen and O'Connor
CMAJ 2007;176:797-805.
ABSTRACT | FULL TEXT  

Acute Phosphodiesterase 5 Inhibition Mimics Hemodynamic Effects of B-Type Natriuretic Peptide and Potentiates B-Type Natriuretic Peptide Effects in Failing But Not Normal Canine Heart
Forfia et al.
J Am Coll Cardiol 2007;49:1079-1088.
ABSTRACT | FULL TEXT  

Management of patients with non-ischaemic cardiomyopathy
Wu
Heart 2007;93:403-408.
FULL TEXT  

Confidentiality Laws And Secrecy In Medical Research: Improving Public Access To Data On Drug Safety
Kesselheim and Mello
Health Aff (Millwood) 2007;26:483-491.
ABSTRACT | FULL TEXT  

Perioperative Nesiritide Versus Milrinone in High-Risk Coronary Artery Bypass Graft Patients
Brackbill et al.
The Annals of Pharmacotherapy 2007;41:427-432.
ABSTRACT | FULL TEXT  

Nesiritide Administration in Patients With Left Ventricular Dysfunction Undergoing Coronary Artery Bypass Surgery
Belenkie
J Am Coll Cardiol 2007;49:727-728.
FULL TEXT  

Projecting future drug expenditures--2007
Hoffman et al.
Am J Health Syst Pharm 2007;64:298-314.
ABSTRACT | FULL TEXT  

Emerging Therapies for the Management of Decompensated Heart Failure: From Bench to Bedside
deGoma et al.
J Am Coll Cardiol 2006;48:2397-2409.
ABSTRACT | FULL TEXT  

Predictors of worsening renal function in adult patients with congestive heart failure receiving recombinant human B-type brain natriuretic peptide (nesiritide)
Iglesias et al.
Nephrol Dial Transplant 2006;21:3458-3465.
ABSTRACT | FULL TEXT  

Haemodynamic and clinical effects of ularitide in decompensated heart failure
Mitrovic et al.
Eur Heart J 2006;27:2823-2832.
ABSTRACT | FULL TEXT  

{beta}-Adrenergic and Atrial Natriuretic Peptide Interactions on Human Cardiovascular and Metabolic Regulation
Birkenfeld et al.
J. Clin. Endocrinol. Metab. 2006;91:5069-5075.
ABSTRACT | FULL TEXT  

Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure.
Hauptman et al.
JAMA 2006;296:1877-1884.
ABSTRACT | FULL TEXT  

Risk of death associated with nesiritide in patients with acutely decompensated heart failure.
Aaronson and Sackner-Bernstein
JAMA 2006;296:1465-1466.
FULL TEXT  

Nesiritide: trials and tribulations.
Arora
J CARDIOVASC PHARMACOL THER 2006;11:165-169.
ABSTRACT  

Perioperative management of chronic heart failure.
Groban and Butterworth
Anesth. Analg. 2006;103:557-575.
ABSTRACT | FULL TEXT  

The rise and fall of Natrecor for congestive heart failure: implications for drug policy.
Kesselheim et al.
Health Aff (Millwood) 2006;25:1095-1102.
ABSTRACT | FULL TEXT  

Treatment of Sleep Apnea in Heart Failure
Arzt and Bradley
Am. J. Respir. Crit. Care Med. 2006;173:1300-1308.
ABSTRACT | FULL TEXT  

Relevance of Brain Natriuretic Peptide in Preload-Dependent Regulation of Cardiac Sarcoplasmic Reticulum Ca2+ ATPase Expression
Kogler et al.
Circulation 2006;113:2724-2732.
ABSTRACT | FULL TEXT  

Contemporary Use of Digoxin in the Management of Cardiovascular Disorders
Gheorghiade et al.
Circulation 2006;113:2556-2564.
FULL TEXT  

Update in critical care 2005.
Milbrandt et al.
Am. J. Respir. Crit. Care Med. 2006;173:833-841.
FULL TEXT  

Nesiritide: The Latest Drug for Treating Heart Failure
Fontana
Crit Care Nurse 2006;26:39-47.
FULL TEXT  

Natriuretic Peptides, Their Receptors, and Cyclic Guanosine Monophosphate-Dependent Signaling Functions
Potter et al.
Endocr. Rev. 2006;27:47-72.
ABSTRACT | FULL TEXT  

Projecting future drug expenditures--2006
Hoffman et al.
Am J Health Syst Pharm 2006;63:123-138.
ABSTRACT | FULL TEXT  

Acute Heart Failure Syndromes: Current State and Framework for Future Research
Gheorghiade et al.
Circulation 2005;112:3958-3968.
FULL TEXT  

Nesiritide for outpatient treatment of heart failure
Bauer and Randazzo
Am J Health Syst Pharm 2005;62:2639-2642.
FULL TEXT  

The Year in Heart Failure
Tang and Francis
J Am Coll Cardiol 2005;46:2125-2133.
FULL TEXT  

Drug Treatment of Systolic and of Diastolic Heart Failure in Elderly Persons
Aronow
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2005;60:1597-1605.
ABSTRACT | FULL TEXT  

Nesiritide--not verified.
Sackner-Bernstein et al.
NEJM 2005;353:1525-1527.
FULL TEXT  

Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness: The ESCAPE Trial
The ESCAPE Investigators and ESCAPE Study Coordina
JAMA 2005;294:1625-1633.
ABSTRACT | FULL TEXT  

Impact of the Pulmonary Artery Catheter in Critically Ill Patients: Meta-analysis of Randomized Clinical Trials
Shah et al.
JAMA 2005;294:1664-1670.
ABSTRACT | FULL TEXT  

The Year in Epidemiology, Health Services, and Outcomes Research
Krumholz
J Am Coll Cardiol 2005;46:1362-1370.
FULL TEXT  

Anemia and Chronic Heart Failure: Are We Asking the Right Questions?
Clark and Cleland
Circulation 2005;112:1681-1683.
FULL TEXT  

Risk of Death With Nesiritide
Burger
JAMA 2005;294:897-897.
FULL TEXT  

Risk of Death With Nesiritide--Reply
Sackner-Bernstein and Aaronson
JAMA 2005;294:898-898.
FULL TEXT  

Risk of Death With Nesiritide
Schuller Gortney and Porter
JAMA 2005;294:897-898.
FULL TEXT  

Controversies in cardiology
Circulation 2005;112:iv-iv.
FULL TEXT  

The Many Possible Benefits of Natriuretic Peptides After Myocardial Infarction
Deschepper
Hypertension 2005;46:271-272.
FULL TEXT  

Nesiritide -- Not Verified
Topol
NEJM 2005;353:113-116.
FULL TEXT  

Nesiritide for Heart Failure: Increased Short-Term Mortality?
JWatch General 2005;2005:6-6.
FULL TEXT  

Does Nesiritide Increase Risks for Renal Failure and Death?
Journal Watch Cardiology 2005;2005:2-2.
FULL TEXT  

What's new in the other general journals
Tonks
BMJ 2005;330:989-990.
FULL TEXT  

Drug for heart failure increases mortality
Spurgeon
BMJ 2005;330:981-981.
FULL TEXT